Literature DB >> 23757504

Developing high-fidelity hepatotoxicity models from pluripotent stem cells.

Claire N Medine1, Baltasar Lucendo-Villarin, Christopher Storck, Faye Wang, Dagmara Szkolnicka, Ferdous Khan, Salvatore Pernagallo, James R Black, Howard M Marriage, James A Ross, Mark Bradley, John P Iredale, Oliver Flint, David C Hay.   

Abstract

Faithfully recapitulating human physiology "in a dish" from a renewable source remains a holy grail for medicine and pharma. Many procedures have been described that, to a limited extent, exhibit human tissue-specific function in vitro. In particular, incomplete cellular differentiation and/or the loss of cell phenotype postdifferentiation play a major part in this void. We have developed an interdisciplinary approach to address this problem, using skill sets in cell biology, materials chemistry, and pharmacology. Pluripotent stem cells were differentiated to hepatocytes before being replated onto a synthetic surface. Our approach yielded metabolically active hepatocyte populations that displayed stable function for more than 2 weeks in vitro. Although metabolic activity was an important indication of cell utility, the accurate prediction of cellular toxicity in response to specific pharmacological compounds represented our goal. Therefore, detailed analysis of hepatocellular toxicity was performed in response to a custom-built and well-defined compound set and compared with primary human hepatocytes. Importantly, stem cell-derived hepatocytes displayed equivalence to primary human material. Moreover, we demonstrated that our approach was capable of modeling metabolic differences observed in the population. In conclusion, we report that pluripotent stem cell-derived hepatocytes will model toxicity predictably and in a manner comparable to current gold standard assays, representing a major advance in the field.

Entities:  

Keywords:  Embryonic stem cells; Hepatocyte differentiation; Stem cell; Toxicity; iPS

Mesh:

Substances:

Year:  2013        PMID: 23757504      PMCID: PMC3697818          DOI: 10.5966/sctm.2012-0138

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  8 in total

Review 1.  Can the pharmaceutical industry reduce attrition rates?

Authors:  Ismail Kola; John Landis
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

Review 2.  The future of drug development: advancing clinical trial design.

Authors:  John Orloff; Frank Douglas; Jose Pinheiro; Susan Levinson; Michael Branson; Pravin Chaturvedi; Ene Ette; Paul Gallo; Gigi Hirsch; Cyrus Mehta; Nitin Patel; Sameer Sabir; Stacy Springs; Donald Stanski; Matthias R Evers; Edd Fleming; Navjot Singh; Tony Tramontin; Howard Golub
Journal:  Nat Rev Drug Discov       Date:  2009-10-09       Impact factor: 84.694

3.  The comparison between conditioned media and serum-free media in human embryonic stem cell culture and differentiation.

Authors:  Zara Hannoun; Judy Fletcher; Sebastian Greenhough; Claire Medine; Kay Samuel; Ruchi Sharma; Anne Pryde; James R Black; James A Ross; Ian Wilmut; John P Iredale; David C Hay
Journal:  Cell Reprogram       Date:  2010-04       Impact factor: 1.987

Review 4.  Pluripotent stem cell-derived hepatocytes: potential and challenges in pharmacology.

Authors:  Dagmara Szkolnicka; Wenli Zhou; Balta Lucendo-Villarin; David C Hay
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013       Impact factor: 13.820

5.  Unbiased screening of polymer libraries to define novel substrates for functional hepatocytes with inducible drug metabolism.

Authors:  David C Hay; Salvatore Pernagallo; Juan Jose Diaz-Mochon; Claire N Medine; Sebastian Greenhough; Zara Hannoun; Joerg Schrader; James R Black; Judy Fletcher; Donna Dalgetty; Alexandra I Thompson; Philip N Newsome; Stuart J Forbes; James A Ross; Mark Bradley; John P Iredale
Journal:  Stem Cell Res       Date:  2010-12-10       Impact factor: 2.020

6.  Generation of functional human hepatic endoderm from human induced pluripotent stem cells.

Authors:  Gareth J Sullivan; David C Hay; In-Hyun Park; Judy Fletcher; Zara Hannoun; Catherine M Payne; Donna Dalgetty; James R Black; James A Ross; Kay Samuel; Gang Wang; George Q Daley; Je-Hyuk Lee; George M Church; Stuart J Forbes; John P Iredale; Ian Wilmut
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

7.  Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling.

Authors:  David C Hay; Judy Fletcher; Catherine Payne; John D Terrace; Ronald C J Gallagher; Jan Snoeys; James R Black; Davina Wojtacha; Kay Samuel; Zara Hannoun; Anne Pryde; Celine Filippi; Ian S Currie; Stuart J Forbes; James A Ross; Philip N Newsome; John P Iredale
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-21       Impact factor: 11.205

8.  SUMOylation of HNF4α regulates protein stability and hepatocyte function.

Authors:  Wenli Zhou; Zara Hannoun; Ellis Jaffray; Claire N Medine; James R Black; Sebastian Greenhough; Liang Zhu; James A Ross; Stuart Forbes; Ian Wilmut; John P Iredale; Ronald T Hay; David C Hay
Journal:  J Cell Sci       Date:  2012-04-14       Impact factor: 5.285

  8 in total
  43 in total

1.  New markers for tracking endoderm induction and hepatocyte differentiation from human pluripotent stem cells.

Authors:  Audrey Holtzinger; Philip R Streeter; Farida Sarangi; Scott Hillborn; Maryam Niapour; Shinichiro Ogawa; Gordon Keller
Journal:  Development       Date:  2015-10-22       Impact factor: 6.868

Review 2.  Human-relevant preclinical in vitro models for studying hepatobiliary development and liver diseases using induced pluripotent stem cells.

Authors:  Pooja Chaudhari; Lipeng Tian; Zhaohui Ye; Yoon-Young Jang
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-26

3.  High-content assays for hepatotoxicity using induced pluripotent stem cell-derived cells.

Authors:  Oksana Sirenko; Jayne Hesley; Ivan Rusyn; Evan F Cromwell
Journal:  Assay Drug Dev Technol       Date:  2013-11-14       Impact factor: 1.738

Review 4.  New substrates for stem cell control.

Authors:  Sara Schmidt; Annamaria Lilienkampf; Mark Bradley
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-07-05       Impact factor: 6.237

5.  Stage-specific regulation of the WNT/β-catenin pathway enhances differentiation of hESCs into hepatocytes.

Authors:  Thomas Touboul; Shujuan Chen; Cuong C To; Sergio Mora-Castilla; Karen Sabatini; Robert H Tukey; Louise C Laurent
Journal:  J Hepatol       Date:  2016-02-26       Impact factor: 25.083

Review 6.  iPS cells: a game changer for future medicine.

Authors:  Haruhisa Inoue; Naoki Nagata; Hiromi Kurokawa; Shinya Yamanaka
Journal:  EMBO J       Date:  2014-02-05       Impact factor: 11.598

Review 7.  Rethinking differentiation: stem cells, regeneration, and plasticity.

Authors:  Alejandro Sánchez Alvarado; Shinya Yamanaka
Journal:  Cell       Date:  2014-03-27       Impact factor: 41.582

Review 8.  Liver diseases in the dish: iPSC and organoids as a new approach to modeling liver diseases.

Authors:  Romina Fiorotto; Mariangela Amenduni; Valeria Mariotti; Luca Fabris; Carlo Spirli; Mario Strazzabosco
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-09-05       Impact factor: 5.187

Review 9.  Stem cell-derived liver cells for drug testing and disease modeling.

Authors:  Matthew D Davidson; Brenton R Ware; Salman R Khetani
Journal:  Discov Med       Date:  2015-05       Impact factor: 2.970

10.  Self-assembled liver organoids recapitulate hepatobiliary organogenesis in vitro.

Authors:  Dipen Vyas; Pedro M Baptista; Matthew Brovold; Emma Moran; Brandon Gaston; Chris Booth; Michael Samuel; Anthony Atala; Shay Soker
Journal:  Hepatology       Date:  2018-01-02       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.